Superworth

Tarsus Pharmaceuticals free cash flow TARS

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
$56M
Latest quarter, Q2 FY26
$57.2M
Fiscal year 2025
−$22.3M

Tarsus Pharmaceuticals' free cash flow was $56M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $57.2M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$22.3Mn/a
FY2024−$84.6Mn/a
FY2023−$119Mn/a
FY2022−$49.5M−1667%
FY2021$3.2Mn/a
FY2020−$21.6Mn/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26$57.2Mn/a$56M
Q1 FY26−$30.5Mn/a−$31.5M
Q4 FY25$13Mn/a−$22.3M
Q3 FY25$16.3Mn/a−$57.5M
Q2 FY25−$30.4Mn/a−$82.8M
Q1 FY25−$21.2Mn/a−$67.9M
Q4 FY24−$22.3Mn/a−$84.6M
Q3 FY24−$8.9Mn/a−$101.7M
Q2 FY24−$15.4Mn/a−$125.5M
Q1 FY24−$38Mn/a−$134.6M
Q4 FY23−$39.3Mn/a−$119M
Q3 FY23−$32.7Mn/a−$90.7M

Against its peers

Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.

CompanyFree cash flow yield
TARSTarsus Pharmaceuticals1.9%
ADMAAdma Biologics4.9%
VCELVericel2.8%
KRYSKrystal Biotech2.8%
RGENRepligen1.1%
MGTXMeiraGTx1.2%
TECHBIO-TECHNE2.3%
HALOHalozyme Therapeutics5.7%
NBIXNeurocrine Biosciences6.0%
EXELExelixis7.3%
INCYIncyte8.2%
Peer median3.9%

Where Tarsus Pharmaceuticals ranks

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Tarsus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.